Moreover, chemotherapy sensitizes tumor cells to zolbetuximab by increasing CLDN18.2 expression, thereafter inducing pro-inflammatory cytokines (25,26). to provide a future perspective for novel cancer treatment. randomized EOX 13.2 months 5.3 months 39% 25% Zhan EOX only (8.6 months 6.0 months) (13). Vomiting was the most frequent toxicity reported in the EOX + zolbetuximab arm (grade […]